ClinicalTrials.gg
CompletedNCT06525506Updated Oct 3, 2025

A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease

A Phase 2 interventional study of IBI311 (20 mg) and IBI311 (3-20 mg) in Thyroid Eye Disease, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Graves Ophthalmopathy with a site in China — 25 open to participants now, 28 under way, 7 of them phase 3. Graves Ophthalmopathy · China.

Enrollment
34th of 45
38 · median 64
Started
2024
with 7 others
Phase 2
6 of 55
2 open now
Registered
27th of 55
by date
Lead sponsor
6 of 55
Innovent Biologics (Suzhou) Co. Ltd.

Among the 55 studies in Graves Ophthalmopathy with a site in China, this one is the 34th largest by enrollment of the 45 interventional ones that give a count, is one of 8 that started in 2024, is one of 6 in phase 2, and was the 27th registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

25 of the 55 studies in Graves Ophthalmopathy with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Graves Ophthalmopathy with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-masked phase II study evaluating the efficacy and safety of IBI311 in subjects with inactive or active thyroid eye disease. Approximately 36 subjects meeting the study eligibility criteria will be randomly assigned to the 3-10 mg group, 3-20 mg group, 10 mg group, or 20 mg group on day 1 in a 1:1:2:2 ratio. Dose conversion of the 3-10 mg or 3-20 mg group was performed at week 12. Active and inactive TED was a stratification factor in this study. Active and inactive TED subjects were enrolled in a 1:1 ratio.

03

Conditions studied

  • Thyroid Eye Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Written .
  2. Male or female subject between the ages of 18 and 80 years at screening.
  3. Weight between 50 kg and 100 kg.
  4. Moderate-to-severe active TED:

    • CAS ≥ 3 in the study eye at screening and baseline;
    • Usually associated with at least two of the following: lid retraction ≥ 2 mm, moderate or severe soft tissue involvement, exophthalmos ≥ 3 mm above normal, and/or inconstant or constant diplopia;
    • ≤ 12 months since the onset of active TED symptoms according to subjects' chief complaint or medical record at screening;

    Inactive TED:

    • According to subjects' chief complaint or medical record at screening, initial diagnosis of TED > 12 months but \< 10 years prior to screening.
    • CAS ≤ 2 in both eyes at screening and baseline and CAS ≤ 2 in both eyes for at least 6 months prior to screening or all of the following at least 6 months prior to screening: a. no progression in proptosis; b. no progression in diplopia; c. no new inflammatory TED symptoms.
    • Exophthalmos ≥ 3 mm above normal.
  5. Exophthalmos ≥ 20 mm in the study eye at baseline.
  6. Female subjects should be fertile women who are sterile or have a negative blood pregnancy test during the screening period and who agree to take measures within 120 days from the screening period to the last medication; Male subjects should agree to use contraception from the screening period to 120 days after the last dose.

Key Exclusion Criteria:

Subjects will be ineligible for study participation if they meet any of the following criteria:

  1. Baseline CAS decreased by ≥ 2 points, or baseline proptosis decreased by ≥ 2 mm as compared with screening.
  2. Visual function impairment due to optic neuropathy, defined as ≥ 2 lines of vision loss, new visual field defect, or color vision impairment secondary to optic nerve involvement within the past 180 days;
  3. Corneal ulcers with no relief after treatment as determined by the investigator;
  4. TED patients who need immediate therapy, orbital radiotherapy, or orbital decompression;
  5. At any time prior to baseline or during the study period planned to receive orbital radiation therapy or TED surgery, including orbital decompression, strabismus surgery, and eyelid retraction correction;
  6. Poorly controlled thyroid function, which was defined as free triiodothyronine (FT3) or free tetraiodothyronine (FT4) deviated more than 50% from the normal reference range of the local research center laboratory at screening.
  7. Either ear had a history of tinnitus or other hearing impairment; or abnormal pure tone audiometry (defined as mean bone conduction threshold [0.5, 1, 2, 4 kHz] ≥25 dB or any bone conduction threshold ≥ 40 dB);
  8. Poorly controlled diabetes at screening, defined as ≥ 9.0% at screening, or any new medication for diabetes within 60 days prior to screening, or any dose adjustment for diabetes drugs > 10%);
  9. Systemic use of glucocorticoids ≤ 30 days prior to screening;
  10. Periorbital use of glucocorticoids ≤ 90 days prior to screening;
  11. Systemic use of ≤ 90 days prior to screening;
  12. Use glucocorticoid eye drops or immunosuppressive eye drops ≤ 30 days prior to screening

12. Use IBI311 or TEPEZZA at any time prior to screening; 13 Use CD20 antibody ≤ 1 year prior to screening, or IL-6R antibody ≤ 180 days prior to screening; 14. Subjects had participated in other interventional clinical trials ≤ 90 days prior to screening, or attempting to participate in other clinical trials during the study period.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Active comparator
    Arm 2: IBI311 (3-20 mg)

    Arm 2: IBI311 (3-20 mg). Participants will receive 8 intravenous infusions of IBI311 with an interval of 3 weeks. Dose conversion was performed at week 12.

    Biological: IBI311 (3-20 mg)

  • Active comparator
    Arm 4: IBI311 (20 mg)

    Arm 4: IBI311 (20 mg). Participants will receive 8 intravenous infusions of IBI311 with an interval of 3 weeks.

    Biological: IBI311 (20 mg)

  • Active comparator
    Arm 3: IBI311 (10 mg)

    Arm 3: IBI311 (10 mg). Participants will receive 8 intravenous infusions of IBI311 with an interval of 3 weeks.

    Biological: IBI311 (10 mg)

  • Active comparator
    Arm 1: IBI311 (3-10 mg)

    Arm 1: IBI311 (3-10 mg). Participants will receive 8 intravenous infusions of IBI311 with an interval of 3 weeks. Dose conversion was performed at week 12.

    Biological: IBI311 (3-10mg/kg)

Interventions

  • BiologicalIBI311 (20 mg)

    Arm 4: 10 mg/kg IBI311 on Day 1, followed by 20 mg/kg IBI311 from week 3 to week 21, Q3W.

  • Arm 2: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 20 mg/kg IBI311 from week 12 to week 21, Q3W.

  • BiologicalIBI311 (10 mg)

    Arm 3: 10 mg/kg IBI311 from day 1 to week 21, Q3W.

  • BiologicalIBI311 (3-10mg/kg)

    Drug page: IBI311

    Arm 1: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 10 mg/kg IBI311 from week 12 to week 21, Q3W.

06

What researchers measure

Primary outcomes

  1. Mean change from Baseline in proptosis in the study eye.

    Proptosis assessment: protrusion of the eye from the orbital rim as measured by Hertel exophthalmometer.

    Time frame: Week 12

  2. Safety and Tolerability

    Incidence, severity, and association with the study drug of ocular and systemic adverse events (AE), treatment-emergent adverse events (TEAE), and serious adverse events (SAE).

    Time frame: After receiving IBI311 treatment for 48 weeks

Secondary outcomes

  1. The proptosis responder rate in the study eye

    Defined as percentage of subjects with a ≥ 2 mm reduction from baseline in proptosis in the study eye, without deterioration \[≥ 2 mm increase\] of proptosis in the non-study eye.

    Time frame: Week 12, 24 and 48

  2. Mean change from Baseline in proptosis in the study eye.

    Proptosis assessment: protrusion of the eye from the orbital rim as measured by Hertel exophthalmometer.

    Time frame: Week 24 and 48

  3. The overall responder rate in the study eye.

    Defined as participants with a reduction in clinical activity score (CAS) of ≥ 2 points, and a reduction in proptosis of ≥ 2 mm in the study eye, and no deterioration (increase in CAS of ≥ 2 points or increase in proptosis of ≥ 2 mm) in the non-study eye.

    Time frame: Week 12, 24 and 48

  4. Percentage of subjects with a CAS of 0 or 1 in the study eye.

    According to the 7-item European Group on Graves' Ophthalmopathy (EUGOGO) amendment, CAS was used to evaluate clinical activity. For each of the following items, one point is given: spontaneous orbital pain, gaze evoked orbital pain, eyelid swelling that is considered to be due to active (inflammatory phase) Graves' ophthalmopathy (GO), eyelid erythema, conjunctival redness that is considered to be due to active (inflammatory phase) GO, chemosis, and inflammation of caruncle or plica. The sum of these points is the total score, with 0 indicating no clinical activity and 7 indicating the most severe clinical activity.

    Time frame: Week 12, 24 and 48

  5. Mean change from Baseline in CAS in the study eye.

    Time frame: Week 12, 24 and 48

  6. Positive responder rate to IBI311 treatment in the study eye.

    Defined as: 1. ≥2 mm reduction of lid aperture; 2. ≥1 point reduction in five-item CAS (excluding subjective, patient-reported spontaneous or gaze-evoked pain), 3. ≥2 mm reduction in exophthalmos, 4. ≥8° increase of eye muscle duction; Improvement in ≥2 features in the study eye without deterioration in the non-study eye

    Time frame: Week 12, 24 and 48

  7. The impact of IBI311 on the quality of life.

    Changes in Graves' Ophthalmopathy Quality of Life (GO-QoL) questionnaire score

    Time frame: Week 12, 24 and 48

  8. The diplopia responder rate

    Defined as subjects with a ≥ 1-point improvement in Gorman diplopia score.

    Time frame: Week 12, 24 and 48

  9. The relapse rate after IBI311 treatment

    Defined as proptosis increased by ≥2 mm from baseline and/or CAS increased by ≥2 points from baseline with total CAS score ≥3 in either eye.

    Time frame: Week 28, 36 and 48

  10. Systemic Pharmacokinetics profile of IBI311

    Descriptive statistics will be performed for concentration data, and the corresponding Pharmacokinetics parameters will be estimated if sufficient data are available.

    Time frame: From Day 1 to week 24

  11. Change from Baseline in MRI in the study eye.

    Changes in exophthalmia from baseline on MRI at week 12, 24, and 48; Changes in the volume and maximum thickness of extraocular muscle, orbital fat and lacrimal gland on MRI from baseline at week 12, 24 and 48; Changes in MRI signal of intraorbital tissue from baseline at week 12, 24 and 48.

    Time frame: Week 12, 24 and 48

07

Study locations

1 site
  • Innovent Biologics (Suzhou) Co. Ltd
    Suzhou, Suzhou 215123, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Jan 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2024
First posted
Jul 29, 2024
StartActual
Sep 4, 2024
Primary completionActual
Jan 9, 2025
CompletionActual
Sep 22, 2025
Last update
Oct 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06525506
Responsible party
Sponsor
First posted
Jul 29, 2024
Start date
Sep 4, 2024
Primary completion
Jan 9, 2025
Completion
Sep 22, 2025
Last update
Oct 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI311

Start the discussion